Literature DB >> 20011699

TLR9 KO mice, haplotypes and CPG indices in Chlamydia trachomatis infection.

S Ouburg1, J M Lyons, J A Land, J E den Hartog, J S A Fennema, H J C de Vries, C A Bruggeman, J I Ito, A S Peña, P S J Lundberg, S A Morré.   

Abstract

Previous studies have investigated the role of Toll-like receptor (TLR)2 and TLR4 in susceptibility to and severity of Chlamydia trachomatis infections. In this study we employ a unique integrated approach to study the role of the intracellular CpG DNA receptor: we use a murine knockout (KO) model to assess TLR9 relevance, study human TLR9 genotypes and haplotypes in sexually transmitted disease (STD) patients and subfertile women with or without tubal pathology and use in silico TLR9 CpG index calculations to assess potential immunostimulatory properties of the Chlamydia bacterium. Although no significant differences in the course of initial infections were observed between KO mice and wild-type mice the TLR9 KO mice showed a significant level of protection upon reinfection (P = 0.02). We did not observe significant differences in genotype frequencies between C. trachomatis-positive and C. trachomatisnegative women (STD patients). However, haplotype analyses revealed a trend between C. trachomatis-positive and C. trachomatis-negative women in the carriage of haplotype IV (P = 0.061; OR: 2.6; 95% CI: 1.0-6.8). In women with subfertility, odds ratios between 2 and 3 were found for tubal pathology risk, but they did not reach significance due to cohort size limitations. Finally, CpG sequence analysis showed mildly immunostimulatory properties for the genomic sequences of Chlamydia serovars B and D. Based on the murine model, human immunogenetic studies and in silico CpG index analyses, TLR9 seems to play a modest role in C. trachomatis infections. Extension of the human cohorts is necessary to significantly prove the effect in humans. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20011699

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  11 in total

1.  Potential protective effect of a G>A SNP in the 3'UTR of HLA-A for Chlamydia trachomatis symptomatology and severity of infection.

Authors:  Marleen E Jansen; Ivan Branković; Joke Spaargaren; Sander Ouburg; Servaas A Morré
Journal:  Pathog Dis       Date:  2015-12-09       Impact factor: 3.166

2.  NOD1 in contrast to NOD2 functional polymorphism influence Chlamydia trachomatis infection and the risk of tubal factor infertility.

Authors:  Ivan Branković; Eleanne F van Ess; Marlies P Noz; Wilhelmina Anke J Wiericx; Joke Spaargaren; Servaas A Morré; Sander Ouburg
Journal:  Pathog Dis       Date:  2015-01-11       Impact factor: 3.166

Review 3.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

4.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

5.  Host Polymorphisms in TLR9 and IL10 Are Associated With the Outcomes of Experimental Haemophilus ducreyi Infection in Human Volunteers.

Authors:  Martin Singer; Wei Li; Servaas A Morré; Sander Ouburg; Stanley M Spinola
Journal:  J Infect Dis       Date:  2016-04-27       Impact factor: 5.226

6.  TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Authors:  Stephan P Verweij; Ouafae Karimi; Jolein Pleijster; Joseph M Lyons; Henry J C de Vries; Jolande A Land; Servaas A Morré; Sander Ouburg
Journal:  Pathog Dis       Date:  2015-11-13       Impact factor: 3.166

7.  CD4+ T cell expression of MyD88 is essential for normal resolution of Chlamydia muridarum genital tract infection.

Authors:  Lauren C Frazer; Jeanne E Sullivan; Matthew A Zurenski; Margaret Mintus; Tammy E Tomasak; Daniel Prantner; Uma M Nagarajan; Toni Darville
Journal:  J Immunol       Date:  2013-09-13       Impact factor: 5.422

8.  CpG DNA analysis of bacterial STDs.

Authors:  Martin Singer; Dewi J de Waaij; Servaas A Morré; Sander Ouburg
Journal:  BMC Infect Dis       Date:  2015-07-16       Impact factor: 3.090

9.  Translational potential into health care of basic genomic and genetic findings for human immunodeficiency virus, Chlamydia trachomatis, and human papilloma virus.

Authors:  Jelena Malogajski; Ivan Brankovic; Stephan P Verweij; Elena Ambrosino; Michiel A van Agtmael; Angela Brand; Sander Ouburg; Servaas A Morré
Journal:  Biomed Res Int       Date:  2013-05-23       Impact factor: 3.411

Review 10.  Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis.

Authors:  Victor H Hu; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2013-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.